Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions
Background. The authors assessed the tolerance and efficacy of intrapleural interleukin‐2 (IL‐2) in patients with malignant effusion. Methods. Twenty‐three patients had a total of 25 metastatic pleural effusions; the patients were treated with recombinant IL‐2 by means of a continuous intrapleural i...
Gespeichert in:
| Veröffentlicht in: | Cancer 1993-06, Vol.71 (12), p.4067-4071 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4071 |
|---|---|
| container_issue | 12 |
| container_start_page | 4067 |
| container_title | Cancer |
| container_volume | 71 |
| creator | Viallat, J. R. Boutin, C. Rey, F. Astoul, Ph Farisse, P. Brandely, M. |
| description | Background. The authors assessed the tolerance and efficacy of intrapleural interleukin‐2 (IL‐2) in patients with malignant effusion.
Methods. Twenty‐three patients had a total of 25 metastatic pleural effusions; the patients were treated with recombinant IL‐2 by means of a continuous intrapleural infusion for 5 days. The daily dosage used in this Phase I/II trial initially was 3 × 106 IU/m2/day; the dosage was increased with every third patient, culminating in a dosage of 24 × 106 IU/m2/day.
Results. One patient who had received the highest dosage died of renal failure on day 8. Ninety‐six percent of patients had Grade 2–3 fever, which was easily controlled with paracetamol administration. Two (8%) patients had pleural empyema. All other side effects were mild and resolved spontaneously by the end of treatment. The objective response rate was 21.7%. The five patients who responded to IL‐2 therapy were alive 7–24 months after treatment, and the survival rate of the whole group was 59% after 13 months.
Conclusion. A daily dose of 10–24 × 106 IU/m2/day of IL‐2 administered intrapleurally gave response rates similar to those reported in the literature using the intravenous route, but a much lower morbidity rate was recorded. |
| doi_str_mv | 10.1002/1097-0142(19930615)71:12<4067::AID-CNCR2820711243>3.0.CO;2-D |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75790191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75790191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5013-6c51b366b1abc8e0dd69e5d707ceafd2206d686dd4689a80b47ea95aafaa1af93</originalsourceid><addsrcrecordid>eNqVkd2K1EAQhRtR1tnVRxByIeJeZKzqTrqTWRGWjD8DiwOi4IVQ9HQ6u635GdMJy9z5CD6jT2KHmR3QC8Grprq-OhzOYWyJMEcA_gIhVzFgwp9jnguQmJ4rXCB_mYBUi8XlahkX74sPPOOgEHkiXok5zIv1BY-X99jseH6fzQAgi9NEfH7ITr3_GkbFU3HCTrIUMqH4jJlVO_R6W9ux13XkmmZsu-HGhq9ddOuGm8h6o2s9uPY6KjtvfdRVkWsH24eTb6799eMnD3PU2EH7IXAmuhOzVTV617X-EXtQ6drbx4f3jH168_pj8S6-Wr9dFZdXsUkBRSxNihsh5Qb1xmQWylLmNi0VKGN1VXIOspSZLMtEZrnOYJMoq_NU60pr1FUuztizve62776P1g_UOG9sXevWdqMnlaocMMcAftmDpu-8721F2941ut8RAk0d0BQiTSHSXQekkJDT1AFR6ID-7IAEARVr4rQM8k8OPsZNY8uj-CH0sH962Osp3KrXrXH-iCWQIJciYNd77NbVdvefFv_p8K-N-A3kvLSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75790191</pqid></control><display><type>article</type><title>Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Viallat, J. R. ; Boutin, C. ; Rey, F. ; Astoul, Ph ; Farisse, P. ; Brandely, M.</creator><creatorcontrib>Viallat, J. R. ; Boutin, C. ; Rey, F. ; Astoul, Ph ; Farisse, P. ; Brandely, M.</creatorcontrib><description>Background. The authors assessed the tolerance and efficacy of intrapleural interleukin‐2 (IL‐2) in patients with malignant effusion.
Methods. Twenty‐three patients had a total of 25 metastatic pleural effusions; the patients were treated with recombinant IL‐2 by means of a continuous intrapleural infusion for 5 days. The daily dosage used in this Phase I/II trial initially was 3 × 106 IU/m2/day; the dosage was increased with every third patient, culminating in a dosage of 24 × 106 IU/m2/day.
Results. One patient who had received the highest dosage died of renal failure on day 8. Ninety‐six percent of patients had Grade 2–3 fever, which was easily controlled with paracetamol administration. Two (8%) patients had pleural empyema. All other side effects were mild and resolved spontaneously by the end of treatment. The objective response rate was 21.7%. The five patients who responded to IL‐2 therapy were alive 7–24 months after treatment, and the survival rate of the whole group was 59% after 13 months.
Conclusion. A daily dose of 10–24 × 106 IU/m2/day of IL‐2 administered intrapleurally gave response rates similar to those reported in the literature using the intravenous route, but a much lower morbidity rate was recorded.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19930615)71:12<4067::AID-CNCR2820711243>3.0.CO;2-D</identifier><identifier>PMID: 8508372</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - pathology ; Adenocarcinoma - secondary ; Antineoplastic agents ; Biological and medical sciences ; dose tolerance ; Drug Tolerance ; Female ; Fever - etiology ; Humans ; Immunotherapy ; Infusions, Parenteral ; Interleukin-2 - administration & dosage ; Interleukin-2 - adverse effects ; Interleukin-2 - therapeutic use ; interleukin‐2 ; intrapleural infusion ; Male ; malignant effusion ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pleura ; Pleural Effusion, Malignant - drug therapy ; Pleural Effusion, Malignant - pathology ; Recombinant Proteins ; Remission Induction ; response ; Survival Rate</subject><ispartof>Cancer, 1993-06, Vol.71 (12), p.4067-4071</ispartof><rights>Copyright © 1993 American Cancer Society</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5013-6c51b366b1abc8e0dd69e5d707ceafd2206d686dd4689a80b47ea95aafaa1af93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4041263$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8508372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Viallat, J. R.</creatorcontrib><creatorcontrib>Boutin, C.</creatorcontrib><creatorcontrib>Rey, F.</creatorcontrib><creatorcontrib>Astoul, Ph</creatorcontrib><creatorcontrib>Farisse, P.</creatorcontrib><creatorcontrib>Brandely, M.</creatorcontrib><title>Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background. The authors assessed the tolerance and efficacy of intrapleural interleukin‐2 (IL‐2) in patients with malignant effusion.
Methods. Twenty‐three patients had a total of 25 metastatic pleural effusions; the patients were treated with recombinant IL‐2 by means of a continuous intrapleural infusion for 5 days. The daily dosage used in this Phase I/II trial initially was 3 × 106 IU/m2/day; the dosage was increased with every third patient, culminating in a dosage of 24 × 106 IU/m2/day.
Results. One patient who had received the highest dosage died of renal failure on day 8. Ninety‐six percent of patients had Grade 2–3 fever, which was easily controlled with paracetamol administration. Two (8%) patients had pleural empyema. All other side effects were mild and resolved spontaneously by the end of treatment. The objective response rate was 21.7%. The five patients who responded to IL‐2 therapy were alive 7–24 months after treatment, and the survival rate of the whole group was 59% after 13 months.
Conclusion. A daily dose of 10–24 × 106 IU/m2/day of IL‐2 administered intrapleurally gave response rates similar to those reported in the literature using the intravenous route, but a much lower morbidity rate was recorded.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - secondary</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>dose tolerance</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>Fever - etiology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Infusions, Parenteral</subject><subject>Interleukin-2 - administration & dosage</subject><subject>Interleukin-2 - adverse effects</subject><subject>Interleukin-2 - therapeutic use</subject><subject>interleukin‐2</subject><subject>intrapleural infusion</subject><subject>Male</subject><subject>malignant effusion</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pleura</subject><subject>Pleural Effusion, Malignant - drug therapy</subject><subject>Pleural Effusion, Malignant - pathology</subject><subject>Recombinant Proteins</subject><subject>Remission Induction</subject><subject>response</subject><subject>Survival Rate</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkd2K1EAQhRtR1tnVRxByIeJeZKzqTrqTWRGWjD8DiwOi4IVQ9HQ6u635GdMJy9z5CD6jT2KHmR3QC8Grprq-OhzOYWyJMEcA_gIhVzFgwp9jnguQmJ4rXCB_mYBUi8XlahkX74sPPOOgEHkiXok5zIv1BY-X99jseH6fzQAgi9NEfH7ITr3_GkbFU3HCTrIUMqH4jJlVO_R6W9ux13XkmmZsu-HGhq9ddOuGm8h6o2s9uPY6KjtvfdRVkWsH24eTb6799eMnD3PU2EH7IXAmuhOzVTV617X-EXtQ6drbx4f3jH168_pj8S6-Wr9dFZdXsUkBRSxNihsh5Qb1xmQWylLmNi0VKGN1VXIOspSZLMtEZrnOYJMoq_NU60pr1FUuztizve62776P1g_UOG9sXevWdqMnlaocMMcAftmDpu-8721F2941ut8RAk0d0BQiTSHSXQekkJDT1AFR6ID-7IAEARVr4rQM8k8OPsZNY8uj-CH0sH962Osp3KrXrXH-iCWQIJciYNd77NbVdvefFv_p8K-N-A3kvLSg</recordid><startdate>19930615</startdate><enddate>19930615</enddate><creator>Viallat, J. R.</creator><creator>Boutin, C.</creator><creator>Rey, F.</creator><creator>Astoul, Ph</creator><creator>Farisse, P.</creator><creator>Brandely, M.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930615</creationdate><title>Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions</title><author>Viallat, J. R. ; Boutin, C. ; Rey, F. ; Astoul, Ph ; Farisse, P. ; Brandely, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5013-6c51b366b1abc8e0dd69e5d707ceafd2206d686dd4689a80b47ea95aafaa1af93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - secondary</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>dose tolerance</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>Fever - etiology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Infusions, Parenteral</topic><topic>Interleukin-2 - administration & dosage</topic><topic>Interleukin-2 - adverse effects</topic><topic>Interleukin-2 - therapeutic use</topic><topic>interleukin‐2</topic><topic>intrapleural infusion</topic><topic>Male</topic><topic>malignant effusion</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pleura</topic><topic>Pleural Effusion, Malignant - drug therapy</topic><topic>Pleural Effusion, Malignant - pathology</topic><topic>Recombinant Proteins</topic><topic>Remission Induction</topic><topic>response</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Viallat, J. R.</creatorcontrib><creatorcontrib>Boutin, C.</creatorcontrib><creatorcontrib>Rey, F.</creatorcontrib><creatorcontrib>Astoul, Ph</creatorcontrib><creatorcontrib>Farisse, P.</creatorcontrib><creatorcontrib>Brandely, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Viallat, J. R.</au><au>Boutin, C.</au><au>Rey, F.</au><au>Astoul, Ph</au><au>Farisse, P.</au><au>Brandely, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-06-15</date><risdate>1993</risdate><volume>71</volume><issue>12</issue><spage>4067</spage><epage>4071</epage><pages>4067-4071</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Background. The authors assessed the tolerance and efficacy of intrapleural interleukin‐2 (IL‐2) in patients with malignant effusion.
Methods. Twenty‐three patients had a total of 25 metastatic pleural effusions; the patients were treated with recombinant IL‐2 by means of a continuous intrapleural infusion for 5 days. The daily dosage used in this Phase I/II trial initially was 3 × 106 IU/m2/day; the dosage was increased with every third patient, culminating in a dosage of 24 × 106 IU/m2/day.
Results. One patient who had received the highest dosage died of renal failure on day 8. Ninety‐six percent of patients had Grade 2–3 fever, which was easily controlled with paracetamol administration. Two (8%) patients had pleural empyema. All other side effects were mild and resolved spontaneously by the end of treatment. The objective response rate was 21.7%. The five patients who responded to IL‐2 therapy were alive 7–24 months after treatment, and the survival rate of the whole group was 59% after 13 months.
Conclusion. A daily dose of 10–24 × 106 IU/m2/day of IL‐2 administered intrapleurally gave response rates similar to those reported in the literature using the intravenous route, but a much lower morbidity rate was recorded.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8508372</pmid><doi>10.1002/1097-0142(19930615)71:12<4067::AID-CNCR2820711243>3.0.CO;2-D</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1993-06, Vol.71 (12), p.4067-4071 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75790191 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adenocarcinoma - secondary Antineoplastic agents Biological and medical sciences dose tolerance Drug Tolerance Female Fever - etiology Humans Immunotherapy Infusions, Parenteral Interleukin-2 - administration & dosage Interleukin-2 - adverse effects Interleukin-2 - therapeutic use interleukin‐2 intrapleural infusion Male malignant effusion Medical sciences Middle Aged Pharmacology. Drug treatments Pleura Pleural Effusion, Malignant - drug therapy Pleural Effusion, Malignant - pathology Recombinant Proteins Remission Induction response Survival Rate |
| title | Intrapleural immunotherapy with escalating doses of interleukin‐2 in metastatic pleural effusions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A04%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intrapleural%20immunotherapy%20with%20escalating%20doses%20of%20interleukin%E2%80%902%20in%20metastatic%20pleural%20effusions&rft.jtitle=Cancer&rft.au=Viallat,%20J.%20R.&rft.date=1993-06-15&rft.volume=71&rft.issue=12&rft.spage=4067&rft.epage=4071&rft.pages=4067-4071&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19930615)71:12%3C4067::AID-CNCR2820711243%3E3.0.CO;2-D&rft_dat=%3Cproquest_cross%3E75790191%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75790191&rft_id=info:pmid/8508372&rfr_iscdi=true |